Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension

NCT00424021 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Hypertension

Interventions

DRUG: ambrisentan

Sponsor

Gilead Sciences